Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05327114 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 2 study of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 20
- Study locations
NCT05327114 is a Phase 2 study of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 201 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05327114, a Phase 2 study of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nipocalimab
Study Locations (20)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Hospital Gral Agudos Ignacio Pirovano - Buenos Aires
- The Alfred Hospital - Melbourne
- Gold Coast University Hospital - Parkwood
- Peking University First Hospital - Beijing
- Xuanwu Hospital ,Capital Medical University - Beijing
- Beijing Tiantan Hospital, Capital Medical University - Beijing
Florida
- Healthcare Innovations Institute Inc - Coral Springs
- Neurology Associates PA - Maitland
New York
- The Neurological Institute of New York - New York
- South Shore Neurologic Associates - Patchogue - Patchogue
Colorado
- IMMUNOe Health and Research Centers - Centennial
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Boston Clinical Trials - Boston
Michigan
- Beaumont Hospital Royal Oak - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2028-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05327114
The ClinicalTrials.gov registry entry for NCT05327114 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polyradiculoneuropathy, Chronic Inflammatory Demyelinating appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05327114 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05327114 about?
NCT05327114 is a clinical study titled "Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
What is the current status of trial NCT05327114?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2022-09-23. Estimated completion is 2028-07-11.
What conditions does trial NCT05327114 study?
This clinical trial studies the following conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
What interventions are being tested in trial NCT05327114?
The interventions under investigation include: Placebo (DRUG), Nipocalimab (DRUG).
Who is sponsoring clinical trial NCT05327114?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05327114 being conducted?
This trial has 20 study locations across Colorado, Florida, Kansas, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.